8-K: ENDRA Life Sciences Faces Nasdaq Delisting Risk

ENDRA Life Sciences received a delisting notice from Nasdaq due to insufficient stockholders' equity, despite previous compliance efforts.

Summary

• ENDRA Life Sciences Inc. has received a notification from Nasdaq indicating it is no longer in compliance with the Minimum Stockholders Equity Requirement.
• The company's stockholders equity as of December 31, 2025, was reported at $2,260,120, falling below the $2,500,000 minimum required for continued listing.
• This non-compliance follows a period where the company had previously regained compliance after an initial notification on May 27, 2025.
• ENDRA Life Sciences intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• The company is exploring options to resolve the deficiency and regain compliance with Nasdaq listing rules.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the immediate risk of delisting from Nasdaq, which poses significant challenges for the company's operations and investor relations.

Negatives

• Stockholders equity of $2,260,120 as of December 31, 2025, is below the Nasdaq minimum requirement of $2,500,000.
• The company is at risk of delisting from The Nasdaq Stock Market LLC.
• Previous efforts to regain compliance were temporary, and the company has again fallen below the required threshold.

Risks

• Delisting from Nasdaq could significantly impact the company's liquidity, trading volume, and ability to access capital markets.
• Failure to regain compliance with the Minimum Stockholders Equity Requirement could lead to the termination of the company's listing.
• There is no assurance that the company will be able to regain compliance or be successful in its appeal to the Nasdaq Hearings Panel.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel and is evaluating options to regain compliance with the Minimum Stockholders Equity Requirement. There can be no assurance of success in regaining compliance or remaining listed on Nasdaq.

Management Comments

• The Company intends to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of a decision by the Panel and the expiration of any extension the Panel may grant to the Company following the hearing.
• The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
• The Company is currently evaluating its available options to resolve the deficiency and regain compliance with the Minimum Stockholders Equity Requirement.
• However, there can be no assurance that the Company will be able to regain compliance with the Minimum Stockholders Equity Requirement, maintain compliance with the other Nasdaq listing requirements or be successful in appealing the delisting determination.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is critical for biotechnology companies, especially those in earlier stages, to access capital and enhance credibility. Failure to meet listing requirements can severely hinder growth prospects and investor confidence.

Stakeholder Impact

• Shareholders: Potential for decreased stock liquidity, increased volatility, and difficulty in trading shares if delisted. Reduced investor confidence.
• Creditors: Increased risk of default if the company faces severe financial distress due to delisting.
• Employees: Potential impact on morale and job security if the company's financial situation deteriorates significantly.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel.
• Evaluate available options to resolve the deficiency and regain compliance with the Minimum Stockholders Equity Requirement.
• Continue ongoing monitoring by Nasdaq regarding compliance with the Minimum Stockholders Equity Requirement.

Key Dates

Recommendation

While the delisting risk is significant, the company intends to appeal and explore options. A 'hold' recommendation reflects the uncertainty and the need for further information on the company's strategy to regain compliance and its financial recovery prospects.

Keywords

Nasdaq delisting, Stockholders Equity, ENDRA Life Sciences, Listing Rule 5550(b)(1), Form 8-K, Compliance Plan, Nasdaq Hearings Panel, Financial Deficiency